The FreeStyle Libre 3 system helped Nathan manage his diabetes. Now, he's sharing his story to help lift stigma.Abbott NORTHAMPTON, MA / ACCESS Newswire / February 7, 2025 / As a competitive powerlift ...

The FreeStyle Libre 3 system helped Nathan manage his diabetes. Now, he's sharing his story to help lift stigma. Abbott NORTHAMPTON, MA / ACCESS Newswire / February 7, 2025 / As a competitive ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management.

In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As ...

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS increase.

Abbott Laboratories is a well-diversified health care company, with four distinct units: medical devices, diagnostics, nutrition and ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), Abbott ...

Continuous glucose monitoring (CGM) is a hot market, not only for people with diabetes but also for those looking to optimize their general health. Abbott's FreeStyle Libre CGM system has been a ...